Programme Thesis
Y Combinator (YC) is a top-tier startup accelerator that provides funding, mentorship, and network access to early-stage startups globally, aiming to help them rapidly scale and achieve product-market fit. The Fall 2026 Batch specifically seeks innovative, high-growth ventures with strong founding teams, and YC's model is built on investing in people and ideas that can become large, impactful companies.
Selection Criteria
• Strong, committed founding team (ideally 2-3 co-founders with complementary skills and deep domain expertise)
• Clear, compelling problem and a novel solution that can scale
• Evidence of traction (users, revenue, partnerships, or strong technical validation)
• Ability to articulate a clear vision and path to growth
• Founder-market fit and deep understanding of the target customer
• Willingness to relocate to San Francisco for the 3-month program (if selected)
• Demonstrated resourcefulness, resilience, and ability to execute
Past Winners / Cohort Profiles
YC has funded over 5,600 startups including Airbnb, Stripe, Dropbox, Reddit, Coinbase, and DoorDash. Typical cohort profiles include technical co-founders with a working prototype or MVP, often from top universities or with prior startup experience. Recent health-tech examples include startups in digital therapeutics, biotech, and AI-driven diagnostics. Named examples from YC's portfolio: CureApp (digital therapeutics for addiction), Spring Health (mental health), and Ro (telehealth).
Ideal Candidate Fingerprint
The platonic ideal applicant is a pair of technical co-founders with a working MVP, early traction (e.g., paying customers or strong pilot data), and a clear, large market opportunity. They have deep domain expertise, a compelling narrative, and the ability to pitch concisely. For health-tech, a validated scientific foundation, regulatory pathway awareness, and a scalable business model are critical.
Recommended Framing
Eniola should position the CCT model and IMPRINT platform as a breakthrough health-tech startup that combines rigorous computational neuroscience with a scalable software platform for addiction-liability screening. Emphasize the strong scientific validation (pre-registered hypotheses, Bayesian modeling, 85.8% reduction in encoding probability), endorsements from leading neuroscientists (Berridge, Gershman, Daw), and the provisional patent as key differentiators. Frame the venture as a high-impact, capital-efficient startup that can disrupt the $100B+ addiction treatment market, with a clear path to clinical trials and B2B partnerships with pharma and healthcare providers.
Watch Out
• Solo founder: YC strongly prefers teams of 2-3 co-founders; Eniola is currently a solo researcher. Consider finding a technical or business co-founder before applying.
• No clear business model or revenue: The application must show a path to monetization (e.g., licensing IMPRINT to pharma, B2B SaaS for clinics).
• Relocation requirement: YC expects founders to be in San Francisco for the 3-month batch; Eniola is based in Lagos, Nigeria, which may require visa arrangements and relocation costs.
• Early stage: YC typically funds startups with at least a prototype and some traction; Eniola's work is still pre-commercialization. A demo of IMPRINT or a pilot partnership would strengthen the application.